• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清白介素-33 和可溶性 ST2 水平及其与白塞病患者疾病活动度的关系。

Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.

机构信息

Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

J Korean Med Sci. 2013 Aug;28(8):1145-53. doi: 10.3346/jkms.2013.28.8.1145. Epub 2013 Jul 31.

DOI:10.3346/jkms.2013.28.8.1145
PMID:23960440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3744701/
Abstract

Interleukin (IL)-33 is an important mediator of innate immunity. Behcet's disease (BD) is an autoinflammatory disorder characterized by hyperactivity of the innate immune response. We measured serum levels of IL-33 and its receptor soluble ST2 (sST2) in patients with BD to investigate their association with disease activity. Serum levels of both IL-33 and sST2 were higher in patients with BD compared with those in normal controls (IL-33: 594.48±175.04 pg/mL in BD and 224.23±56.64 pg/mL in normal controls [P=0.048], sST2: 99.01±15.92 pg/mL in BD and 23.56±3.25 pg/mL in normal controls [P<0.001]). IL-33 and sST2 expression in skin tissue, as shown by immunohistochemistry, was higher in patients with BD compared with that in the normal controls. Serum sST2 level correlated significantly with the BD currently active form (BDCAF), Iranian BD dynamic activity measure (IBDDAM), erythrocyte sedimentation rate and C-reactive protein. Multiple linear regression showed that serum sST2 was an independent factor associated with IBBDAM (regression coefficient, 0.374; P=0.004), and BDCAF (regression coefficient, 0.236; P=0.047). These results demonstrate that IL-33 and sST2 are highly expressed in patients with BD and that serum sST2 is an independent factor associated with IBDDAM and BDCAF, suggesting a potential role for sST2 as a surrogate marker of disease activity in patients with BD.

摘要

白细胞介素 (IL)-33 是先天免疫的重要介质。白塞病 (BD) 是一种以先天免疫反应过度活跃为特征的自身炎症性疾病。我们测量了 BD 患者的血清 IL-33 及其受体可溶性 ST2(sST2)水平,以研究它们与疾病活动的关系。BD 患者的血清 IL-33 和 sST2 水平均高于正常对照组(IL-33:BD 为 594.48±175.04 pg/mL,正常对照组为 224.23±56.64 pg/mL [P=0.048],sST2:BD 为 99.01±15.92 pg/mL,正常对照组为 23.56±3.25 pg/mL [P<0.001])。免疫组织化学显示,BD 患者皮肤组织中的 IL-33 和 sST2 表达高于正常对照组。血清 sST2 水平与 BD 目前的活动形式(BDCAF)、伊朗 BD 动态活动量表(IBDDAM)、红细胞沉降率和 C 反应蛋白显著相关。多元线性回归显示,血清 sST2 是与 IBDDAM 相关的独立因素(回归系数 0.374,P=0.004),也是与 BDCAF 相关的独立因素(回归系数 0.236,P=0.047)。这些结果表明,IL-33 和 sST2 在 BD 患者中高度表达,血清 sST2 是与 IBDDAM 和 BDCAF 相关的独立因素,提示 sST2 可能作为 BD 患者疾病活动的替代标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/8f3574ef162a/jkms-28-1145-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/039bff093d2f/jkms-28-1145-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/720bf9de58f9/jkms-28-1145-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/7d8acbe8fd74/jkms-28-1145-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/8f3574ef162a/jkms-28-1145-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/039bff093d2f/jkms-28-1145-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/720bf9de58f9/jkms-28-1145-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/7d8acbe8fd74/jkms-28-1145-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6557/3744701/8f3574ef162a/jkms-28-1145-g004.jpg

相似文献

1
Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.血清白介素-33 和可溶性 ST2 水平及其与白塞病患者疾病活动度的关系。
J Korean Med Sci. 2013 Aug;28(8):1145-53. doi: 10.3346/jkms.2013.28.8.1145. Epub 2013 Jul 31.
2
Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus.血清 IL-33 和可溶性 ST2 水平及其与系统性红斑狼疮疾病活动的关系。
Rheumatology (Oxford). 2010 Mar;49(3):520-7. doi: 10.1093/rheumatology/kep402. Epub 2009 Dec 21.
3
Increased serum interleukin-32 levels in patients with Behçet's disease.白塞病患者血清白细胞介素-32水平升高。
Int J Rheum Dis. 2018 Dec;21(12):2167-2174. doi: 10.1111/1756-185X.13072. Epub 2017 Apr 5.
4
Lack of association between serum IL-9 levels and Behçet's disease.血清白介素-9 水平与贝赫切特病无关。
Immunol Lett. 2019 Jul;211:23-27. doi: 10.1016/j.imlet.2019.05.007. Epub 2019 May 13.
5
Serum IL-33 levels and skin mRNA expression in Behçet's disease.血清白介素-33 水平和白塞病皮肤的 mRNA 表达。
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):6-14. Epub 2013 Mar 4.
6
Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis.可溶性 ST2 作为全身型幼年特发性关节炎疾病活动的标志物。
Cytokine. 2013 May;62(2):272-7. doi: 10.1016/j.cyto.2013.03.007. Epub 2013 Apr 3.
7
Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease.检测慢性肾脏病患者血清中白细胞介素-33 和可溶性 ST2 的特点及其与疾病严重程度的关系。
J Clin Immunol. 2012 Jun;32(3):587-94. doi: 10.1007/s10875-011-9622-7. Epub 2011 Dec 28.
8
Interleukin-17 mRNA expression and serum levels in Behçet's disease.白塞病患者白细胞介素-17 mRNA 表达和血清水平。
Cytokine. 2020 Mar;127:154994. doi: 10.1016/j.cyto.2020.154994. Epub 2020 Jan 14.
9
Serum Interleukin-33 in Behcet's Disease: Its Relation to Disease Activity and Clinical Manifestations.白塞病患者血清白细胞介素-33:其与疾病活动度及临床表现的关系
Egypt J Immunol. 2015 Jun;22(2):1-8.
10
The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid.大疱性类天疱疮患者血清和水疱液中可溶性 ST2 水平。
Eur J Dermatol. 2012 May-Jun;22(3):333-6. doi: 10.1684/ejd.2012.1706.

引用本文的文献

1
Difamilast, a Topical Phosphodiesterase 4 Inhibitor, Produces Soluble ST2 via the AHR-NRF2 Axis in Human Keratinocytes.二芳基马来酰亚胺(Difamilast),一种局部磷酸二酯酶 4 抑制剂,通过人角质形成细胞中的 AHR-NRF2 轴产生可溶性 ST2。
Int J Mol Sci. 2024 Jul 19;25(14):7910. doi: 10.3390/ijms25147910.
2
Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances.贝赫切特葡萄膜炎的解码:发病机制和治疗进展的深入综述。
J Neuroinflammation. 2024 May 22;21(1):133. doi: 10.1186/s12974-024-03123-6.
3
IL-33 in Rheumatic Diseases.风湿性疾病中的白细胞介素-33

本文引用的文献

1
IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis.白介素-33 在巨细胞动脉炎患者的炎动脉中过表达。
Ann Rheum Dis. 2013 Feb;72(2):258-64. doi: 10.1136/annrheumdis-2012-201309. Epub 2012 Aug 7.
2
Elevated serum interleukin-33 levels in patients with Henoch-Schönlein purpura.血清白细胞介素-33 水平在过敏性紫癜患者中的升高。
Arch Dermatol Res. 2013 Mar;305(2):173-7. doi: 10.1007/s00403-012-1268-7. Epub 2012 Jul 27.
3
IL-33 regulates TNF-α dependent effects in synovial fibroblasts.IL-33 调节滑膜成纤维细胞中 TNF-α 依赖的效应。
Front Med (Lausanne). 2021 Sep 13;8:739489. doi: 10.3389/fmed.2021.739489. eCollection 2021.
4
A single nucleotide polymorphism in the gene is associated with Behcet's disease in a Chinese Han population.该基因中的一个单核苷酸多态性与中国汉族人群的白塞病相关。
Int J Ophthalmol. 2021 Sep 18;14(9):1315-1320. doi: 10.18240/ijo.2021.09.04. eCollection 2021.
5
Genetic Association of Interleukin 33/ST2 Polymorphisms With Behcet's Uveitis.白细胞介素33/ST2基因多态性与白塞氏葡萄膜炎的遗传关联
Front Immunol. 2021 Mar 25;12:589639. doi: 10.3389/fimmu.2021.589639. eCollection 2021.
6
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?不完美的风暴:白细胞介素-33是新冠病毒的致命弱点吗?
Lancet Rheumatol. 2020 Dec;2(12):e779-e790. doi: 10.1016/S2665-9913(20)30340-4. Epub 2020 Oct 9.
7
Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet's disease.活动期和静止期贝赫切特眼病患者血清 IL-4、IL-12、IL-13、IL-27 和 IL-33 水平。
Int Ophthalmol. 2020 Dec;40(12):3441-3451. doi: 10.1007/s10792-020-01530-1. Epub 2020 Jul 29.
8
Mast cells enhance sterile inflammation in chronic nonbacterial osteomyelitis.肥大细胞增强慢性非细菌性骨髓炎中的无菌性炎症。
Dis Model Mech. 2019 Aug 20;12(8):dmm040097. doi: 10.1242/dmm.040097.
9
Interaction between IL-33 Gene Polymorphisms and Current Smoking with Susceptibility to Systemic Lupus Erythematosus.白细胞介素 33 基因多态性与当前吸烟状态在系统性红斑狼疮易感性中的交互作用。
J Immunol Res. 2019 Mar 11;2019:1547578. doi: 10.1155/2019/1547578. eCollection 2019.
10
Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.穿越时光编织丝线:白塞病的过去、现在与未来
Int J Rheumatol. 2017;2017:2160610. doi: 10.1155/2017/2160610. Epub 2017 Sep 10.
Int J Mol Med. 2012 Apr;29(4):530-40. doi: 10.3892/ijmm.2012.883. Epub 2012 Jan 10.
4
Serum levels of IL-33 is increased in patients with ankylosing spondylitis.血清中白细胞介素-33 水平在强直性脊柱炎患者中升高。
Clin Rheumatol. 2011 Dec;30(12):1583-8. doi: 10.1007/s10067-011-1843-x. Epub 2011 Oct 4.
5
Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis.检测类风湿关节炎患者的白细胞介素-33(IL-33)及其受体(sST2 和 ST2L)。
J Korean Med Sci. 2011 Sep;26(9):1132-9. doi: 10.3346/jkms.2011.26.9.1132. Epub 2011 Sep 1.
6
Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33.IL-33 在类风湿关节炎发病机制中的作用:依那西普对血清 IL-33 水平的影响。
Mod Rheumatol. 2012 Feb;22(1):89-93. doi: 10.1007/s10165-011-0480-1. Epub 2011 Jun 15.
7
Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population.血清白介素-33 水平升高与中国人群系统性红斑狼疮临床和实验室特征的相关性。
Clin Exp Med. 2011 Jun;11(2):75-80. doi: 10.1007/s10238-010-0115-4. Epub 2010 Oct 21.
8
IL-33 is a crucial amplifier of innate rather than acquired immunity.IL-33 是先天免疫而非获得性免疫的关键放大器。
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18581-6. doi: 10.1073/pnas.1003059107. Epub 2010 Oct 11.
9
Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis.血清白细胞介素 33 水平升高与类风湿关节炎患者自身抗体产生有关。
J Rheumatol. 2010 Oct;37(10):2006-13. doi: 10.3899/jrheum.100184. Epub 2010 Aug 3.
10
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy.IL-33 可诱导类风湿关节炎中的中性粒细胞迁移,是抗 TNF 治疗的靶点。
Ann Rheum Dis. 2010 Sep;69(9):1697-703. doi: 10.1136/ard.2009.122655. Epub 2010 May 14.